Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis

Giuseppe Di Lorenzo, R. Autorino, G. Bruni, G. Cartentì, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, M. Giuliano, A. Gonnella, C. De Nunzio, M. Rizzo, V. Montesarchio, M. Ewer, S. De Placido

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recent data have shown that cardiotoxicity represents a potentially important side-effect in patients treated with sunitinib. We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent. Patients and methods: The medical records of 175 patients with metastatic RCC treated with sunitinib at eight Italian institutions were retrospectively reviewed. Alterations in left ventricular ejection fraction (LVEF) and blood pressure were evaluated. Patients with preexisting cardiac risk factors were specifically scrutinized for increased expression of cardiac changes. Results: Grade 3 hypertension was seen in 17 patients (9.7%); in 12 of these 17, hypertension developed after receiving the third sunitinib cycle. Among these 17 patients, 12 (70.6%) also experienced left ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%). Significant univariate associations for predictors of CHF were history of hypertension (P = 0.008), history of coronary heart disease (P = 0.0005) and prior treatment with an angiotensin-converting enzyme inhibitor (P = 0.04). Multivariate analysis suggested that a history of coronary artery disease [odds ratio (OR) 18, 95% confidence interval (CI) 4-160, P = 0.005] and hypertension (OR 3, 95% CI 1.5-80, P = 0.04) was the only significant independent predictors of CHF. Conclusions: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.

Original languageEnglish
Pages (from-to)1535-1542
Number of pages8
JournalAnnals of Oncology
Volume20
Issue number9
DOIs
Publication statusPublished - 2009

Keywords

  • Cardiotoxicity
  • Hypertension
  • Metastatic kidney cancer
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis'. Together they form a unique fingerprint.

Cite this